Systemic hormonal drugs. Simple systemic corticosteroids. Glucocorticoids
Prednisolone is a dehydrogenated analogue of hydrocortisone. The medicine has an anti-inflammatory, anti-allergic, desensitising, anti-shock and immunosuppressive action.
Rheumatic fever, rheumatic carditis, chorea minor.
Systemic connective tissue diseases (systemic lupus erythematosus, scleroderma, polyarteritis nodosa, dermatomyositis).
Acute and chronic inflammatory joint diseases (rheumatoid arthritis, juvenile arthritis, ankylosing spondylitis, gouty and psoriatic arthritis, polyarthritis, humeroscapular periarthritis, osteoarthritis (including post-traumatic), adult-onset Still's disease, bursitis, nonspecific tendosynovitis, synovitis, epicondylitis).
Bronchial asthma, acute severe asthma.
Interstitial lung diseases (acute alveolitis, pulmonary fibrosis, stage 2-3 sarcoidosis), lung cancer (in combination with cytostatics), berylliosis, aspiration pneumonia (combination with specific therapy), Löffler's eosinophilic pneumonia, tuberculosis (lung tuberculosis, tuberculous meningitis) — in combination with specific therapy.
Primary and secondary adrenal insufficiency (including conditions after removal of the adrenal glands), congenital adrenal hyperplasia, adrenogenital syndrome, subacute thyroiditis).
Acute and chronic allergic diseases (drug and food allergies, serum sickness, pollinosis, atopic dermatitis, contact dermatitis involving a large body area, urticaria, allergic rhinitis, angioedema, Stevens-Jonson syndrome, toxicoderma).
Autoimmune diseases (including acute glomerulonephritis).
Inflammatory gastrointestinal diseases (nonspecific ulcerative colitis, Crohn's disease, local enteritis).
Blood and haematopoietic diseases (agranulocytosis, panmyelopathy, myeloma, acute lymphoid and myeloid leukemia, lymphogranulomatosis, thrombocytopenic purpura, secondary thrombocytopenia in adults, autoimmune haemolytic anaemia, erythroblastopenia, congenital (erythroid) hypoplastic anaemia).
Autoimmune and other skin diseases (eczema, seborrheic dermatitis, psoriasis, Lyell's syndrome, bullous dermatitis herpetiformis, pemphigus, exfoliative dermatitis).
Postoperative, post-radiation, post-traumatic brain oedema, in brain tumour (should be used after parenteral glucocorticosteroids).
Eye diseases, including allergic and autoimmune diseases (sympathetic ophthalmia, allergic conjunctivitis, allergic corneal ulcer, non-suppurative keratitis, iridocyclitis, iritis, severe slow anterior and posterior uveitis, choroiditis, optic neuritis).
Prevention of transplant rejection.
Hypercalcemia associated with cancer.
For prevention and elimination of nausea and vomiting in cytostatic therapy.
The dosing should be determined on an individual basis. When administered, the circadian rhythm of glucocorticoid secretion should be taken into account - most of the dose (2/3) or the entire dose should be taken in the morning, around 8 a.m., and 1/3 of the dose should be taken in the evening.